Dexter, David T.

Mitochondrial Complex I Deficiency in Parkinson's Disease

Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and Pathology

Cited by 2,283

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsGlutathione Transferases and Polymorphisms

Cited by 1,161

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease

Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 1,149

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia

DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain

Neurological diseases and metabolismParkinson's Disease Mechanisms and Treatments

Cited by 1,043

Increased nigral iron content in postmortem parkinsonian brain

Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 963

Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease

Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain

Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments

Cited by 433

Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition

Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 414

Decreased ferritin levels in brain in Parkinson's disease

Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A. J., Wells, F. R., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 258

Metal based neurodegenerative diseases—From molecular mechanisms to therapeutic strategies

Crichton, R. R., Dexter, D. T., & Ward, R. J. (2008) · Coordination Chemistry Reviews

Trace Elements in HealthParkinson's Disease Mechanisms and Treatments

Cited by 252

Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6‐hydroxydopamine model of Parkinson’s disease

Marinova‐Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2009) · Journal of Neurochemistry

Neuroinflammation and Neurodegeneration MechanismsParkinson's Disease Mechanisms and Treatments

Cited by 217

Effects of Antemortem and Postmortem Variables on Human Brain mRNA Quality: A BrainNet Europe Study

Durrenberger, P. F., Fernando, S., Kashefi, S. N., Ferrer, I., Hauw, J.-J., Seilhean, D., Smith, C., Walker, R., Al-Sarraj, S., Troakes, C., et al. (2010) · Journal of Neuropathology & Experimental Neurology

Molecular Biology Techniques and ApplicationsRNA Research and Splicing

Cited by 161

Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease

Pienaar, I. S., Lee, C. H., Elson, J. L., McGuinness, L., Gentleman, S. M., Kalaria, R. N., & Dexter, D. T. (2015) · Neurobiology of Disease

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 125

Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease

Broom, L., Marinova-Mutafchieva, L., Sadeghian, M., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2011) · Free Radical Biology and Medicine

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 96

Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study

Durrenberger, P. F., Grünblatt, E., Fernando, F. S., Monoranu, C. M., Evans, J., Riederer, P., Reynolds, R., & Dexter, D. T. (2012) · Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 63

The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease

Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 46

Accelerating Parkinson’s Disease drug development with federated learning approaches

Khanna, A., Adams, J., Antoniades, C., Bloem, B. R., Carroll, C., Cedarbaum, J., Cosman, J., Dexter, D. T., Dockendorf, M. F., Edgerton, J., et al. (2024) · npj Parkinson's Disease

Privacy-Preserving Technologies in DataParkinson's Disease Mechanisms and Treatments

Cited by 21